Humacyte (NASDAQ:HUMA) Stock Rating Raised to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) to a sell rating in a research note released on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $2.00 price target on shares of Humacyte in a report on Tuesday, November 10th. Cantor Fitzgerald set a $1.00 price target on shares of Humacyte in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Benchmark reduced their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. Finally, Williams Trading set a $1.00 price objective on shares of Humacyte in a research report on Friday, October 16th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Humacyte currently has an average rating of “Moderate Buy” and a consensus price target of $4.48.

Humacyte Stock Down 6.2%

Shares of NASDAQ:HUMA traded down $0.04 on Friday, hitting $0.56. 4,625,603 shares of the company’s stock were exchanged, compared to its average volume of 4,968,351. The firm’s 50-day moving average is $0.49 and its 200 day moving average is $0.78. The company has a market capitalization of $155.12 million, a PE ratio of -1.27 and a beta of 2.64. Humacyte has a 1-year low of $0.34 and a 1-year high of $1.52. The company has a debt-to-equity ratio of 3.65, a quick ratio of 5.74 and a current ratio of 3.34.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative net margin of 3,955.05% and a negative return on equity of 612.88%. Sell-side analysts predict that Humacyte will post -0.38 EPS for the current year.

Institutional Trading of Humacyte

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Humacyte during the second quarter worth approximately $3,777,000. Alyeska Investment Group L.P. purchased a new stake in Humacyte in the second quarter valued at approximately $4,700,000. GSA Capital Partners LLP acquired a new stake in shares of Humacyte in the second quarter valued at approximately $785,000. HBK Investments L P acquired a new stake in shares of Humacyte in the second quarter valued at approximately $617,000. Finally, Miramontes Capital LLC acquired a new stake in shares of Humacyte in the second quarter valued at approximately $85,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Humacyte

These are some of the HUMA headlines that stood out recently:

• Positive Sentiment: HC Wainwright raised its estimated loss per share for FY2026 to $0.39 from $0.46, and narrowed its projected losses for Q4 2026 and Q1 2027. The firm maintained its Buy rating.
• Positive Sentiment: StoneX reiterated its Speculative Buy rating, while a separate roundup highlighted Humacyte among healthcare stocks with bullish analyst views. StoneX Reiterates Speculative Buy Rating on Humacyte Analysts Are Bullish on These Healthcare Stocks
• Negative Sentiment: HC Wainwright trimmed estimates for FY2027 and FY2028, and lowered projected Q3 and Q4 2027 results. It now expects a $0.31-per-share loss in FY2027 and a $0.11 loss in FY2028, signaling a slower path to profitability than previously forecast.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.